TCT ’22: Abbott Presents Late-Breaking Data

Abbott presented data from five late-breaking presentations demonstrating benefits of its minimally invasive devices to treat structural heart diseases at this year’s Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation in Boston (September 16-19, 2022).
 
Data included findings reinforcing the MitraClip transcatheter edge-to-edge repair (TEER) device to treat mitral regurgitation (MR). Result were also shared for TriClip tricuspid heart valve repair, Amplatzer Amulet left atrial appendage occluder (LAAO) to complete LAA closure and reduce stroke risk, and the Portico self-expanding transcatheter aortic valve implantation (TAVI) system.
 
The over 1,000-patient MitraClip EXPAND G4 post-approval study showed “significant” MR reduction in 91% of patients. 83% of patients achieved New York Heart Association (NYHA) Functional Class I/II, improvement of 52% from 31% of baseline, and an 18-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.
 
The 700-patient TriClip TRILUMINATE pivotal trial results showed 99% implant success rate, at least one-grade tricuspid regurgitation (TR) reduction in 91% of patients, and around 17-point improvement in the KCCQ score.
 
Three-year, 1,800-patient Amulet IDE study outcomes showed device-related factors like thrombosis or peri-device leak more grequently preceded strokes with Boston Scientific’s Watchman than with Amulet. Cardiovascular and all-cause death trended higher on Watchman than Amulet, as well.
 
Amulet’s PREDICT LAA trial studied whether cardiac computed tomography-based computational models using the FEops HEARTguide helped plan Amulet procedures. At three months, data showed improved procedural efficiency and safety outcomes when Amplatzer Amulet LAA occluder surgeries were planned with HEARTguide.
 
The Portico CONFIDENCE Registry real-world study evaluated Portico TAVI with the first-gen delivery system in 501 patients and second-gen FlexNav delivery in 500 patients. 30-day, late-breaking data for hemodynamics at 30 days and one-year survival was presented on 9/18.